Enzalutamide (BioDeep_00000178720)
human metabolite blood metabolite
代谢物信息卡片
4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide
化学式: C21H16F4N4O2S (464.0930044)
中文名称: 恩杂鲁胺
谱图信息:
最多检出来源 Homo sapiens(blood) 80%
分子结构信息
SMILES: CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
InChI: InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)
描述信息
L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02B - Hormone antagonists and related agents > L02BB - Anti-androgens
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C146993 - Androgen Receptor Inhibitor
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C242 - Anti-Androgen
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
9 个代谢物同义名
4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide; 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-D3)benzamide; 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-benzamide; Enzalutamide D3; Enzalutamide; MDV-3100; MDV 3100; MDV3100; XTANDI
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:68534
- PubChem: 15951529
- HMDB: HMDB0251831
- DrugBank: DB08899
- ChEMBL: CHEMBL1082407
- Wikipedia: Enzalutamide
- chemspider: 13093347
- CAS: 915087-33-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Wenhui Yao, Rongpin Tao, Yue Xu, Zhe-Sheng Chen, Xuansheng Ding, Lisheng Wan. AR/RKIP pathway mediates the inhibitory effects of icariin on renal fibrosis and endothelial-to-mesenchymal transition in type 2 diabetic nephropathy.
Journal of ethnopharmacology.
2024 Feb; 320(?):117414. doi:
10.1016/j.jep.2023.117414. [PMID: 37977422] - Linjin Li, Dake Chen, Xiang Chen, Jianlong Zhu, Wenshuo Bao, Chengpeng Li, Feilong Miao, Rui Feng. An androgen receptor-based signature to predict prognosis and identification of ORC1 as a therapeutical target for prostate adenocarcinoma.
PeerJ.
2024; 12(?):e16850. doi:
10.7717/peerj.16850. [PMID: 38562999] - Rui Sun, Binyuan Yan, Hao Li, Donglin Ding, Liguo Wang, Jun Pang, Dingwei Ye, Haojie Huang. Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis.
Cancer research.
2023 10; 83(19):3192-3204. doi:
10.1158/0008-5472.can-23-0285. [PMID: 37527336] - Xin Wang, Lina Chang, Zhenhua Li, Yuanfang Jiang, Yue Chen, Xinli Jia, Qiye Wang, Xiaolu Ren, Zhifang Ma, Wei Zhang. Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system.
Expert opinion on drug safety.
2023 Jul; 22(11):1099-1103. doi:
10.1080/14740338.2023.2255524. [PMID: 37670490] - Xueting Guo, Yibin Guo, Maolian Zhang, Bing Yang, Hao Liu, Tian Yin, Yu Zhang, Haibing He, Yanjiao Wang, Dongchun Liu, Jingxin Gou, Xing Tang. A comparative study on in vitro and in vivo characteristics of enzalutamide nanocrystals versus amorphous solid dispersions and a better prediction for bioavailability based on 'spring-parachute' model.
International journal of pharmaceutics.
2022 Nov; 628(?):122333. doi:
10.1016/j.ijpharm.2022.122333. [PMID: 36283642] - Duy T Nguyen, Wei Yang, Arun Renganathan, Cody Weimholt, Duminduni H Angappulige, Thanh Nguyen, Robert W Sprung, Gerald L Andriole, Eric H Kim, Nupam P Mahajan, Kiran Mahajan. Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022 09; 28(18):4131-4145. doi:
10.1158/1078-0432.ccr-21-3603. [PMID: 35849143] - Klara K Ternov, Jens Sønksen, Mikkel Fode, Henriette Lindberg, Caroline Kistorp, Rasmus Bisbjerg, Jens Faber, Tobias W Klausen, Ganesh Palapattu, Peter B Østergren. Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT).
European journal of cancer (Oxford, England : 1990).
2022 08; 171(?):75-84. doi:
10.1016/j.ejca.2022.04.034. [PMID: 35709600] - Xi Chen, Yechen Wu, Xinan Wang, Chengdang Xu, Licheng Wang, Jingang Jian, Denglong Wu, Gang Wu. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
European journal of medical research.
2022 Jul; 27(1):105. doi:
10.1186/s40001-022-00730-y. [PMID: 35780240] - A Küçükarda, A Gökyer, I Gökmen, E Özcan, M B Hacıoğlu, B Erdoğan, S Uzunoğlu, I Çiçin. Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.
Actas urologicas espanolas.
2022 06; 46(5):301-309. doi:
10.1016/j.acuroe.2021.12.005. [PMID: 35256324] - Carlos G Wambier, Gerard J Nau. Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93: Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients.
European urology.
2022 Jun; 81(6):e141-e142. doi:
10.1016/j.eururo.2022.01.049. [PMID: 35304000] - Zejie Mei, Tao Yang, Ying Liu, Yuanyuan Gao, Zemin Hou, Qian Zhuang, Dongyin He, Xuebin Zhang, Qilong Tan, Xuyou Zhu, Yingyi Qin, Xi Chen, Chengdang Xu, Cuidong Bian, Xinan Wang, Chenyang Wang, Denglong Wu, Shengsong Huang, Zhenfei Li. Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment.
Cell reports. Medicine.
2022 05; 3(5):100608. doi:
10.1016/j.xcrm.2022.100608. [PMID: 35584629] - Srinivasu Poondru, Vitalii Ghicavii, Reza Khosravan, Pooja Manchandani, Nakyo Heo, Selina Moy, Tomasz Wojtkowski, Melanie Patton, Gabriel P Haas. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
Clinical and translational science.
2022 05; 15(5):1131-1142. doi:
10.1111/cts.13229. [PMID: 35118821] - S H Verhulst, E Boerrigter, S Ras, N P van Erp, P Hamberg. Unintentional combining enzalutamide with a moderate CYP2C8 inhibitor in a patient with metastatic castration-resistant prostate cancer: a case report.
Cancer chemotherapy and pharmacology.
2022 04; 89(4):539-542. doi:
10.1007/s00280-021-04379-y. [PMID: 35059789] - Sanghee Lee, Theresa R Mendoza, Danielle N Burner, Michelle T Muldong, Christina C N Wu, Catalina Arreola-Villanueva, Abril Zuniga, Olga Greenburg, William Y Zhu, Jamillah Murtadha, Evodie Koutouan, Naomi Pineda, Hao Pham, Sung-Gu Kang, Hyun Tae Kim, Gabriel Pineda, Kathleen M Lennon, Nicholas A Cacalano, Catriona H M Jamieson, Christopher J Kane, Anna A Kulidjian, Terry Gaasterland, Christina A M Jamieson. Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic Prostate Cancer Organoids.
International journal of molecular sciences.
2022 Mar; 23(6):. doi:
10.3390/ijms23063203. [PMID: 35328625] - Karin Welén, Ebba Rosendal, Magnus Gisslén, Annasara Lenman, Eva Freyhult, Osvaldo Fonseca-Rodríguez, Daniel Bremell, Johan Stranne, Åse Östholm Balkhed, Katarina Niward, Johanna Repo, David Robinsson, Anna J Henningsson, Johan Styrke, Martin Angelin, Elisabeth Lindquist, Annika Allard, Miriam Becker, Stina Rudolfsson, Robert Buckland, Camilla Thellenberg Carlsson, Anders Bjartell, Anna C Nilsson, Clas Ahlm, Anne-Marie Fors Connolly, Anna K Överby, Andreas Josefsson. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data.
European urology.
2022 03; 81(3):285-293. doi:
10.1016/j.eururo.2021.12.013. [PMID: 34980495] - Michalis Liontos, Evangelos Terpos, Elena Kunadis, Flora Zagouri, Alexandros Briasoulis, Efi Skafida, Oraianthi Fiste, Christos Markellos, Angeliki Andrikopoulou, Sentiljana Gumeni, Maria Kaparelou, Konstantinos Koutsoukos, Maria Gavriatopoulou, Efstathios Kastritis, Ioannis P Trougakos, Meletios- Athanasios Dimopoulos. Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients.
Prostate cancer and prostatic diseases.
2022 03; 25(1):117-118. doi:
10.1038/s41391-021-00455-9. [PMID: 34628475] - Haiping Ma, Weidong Xu, Jin Ni, Naping Zhao, Shouyan Tang, Song Li, Tingting Cai, Jianping Xiu, Xin Kang, Shen Gao, Li Zhang, Tie Zhou. Phase I clinical trial of HC-1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single-dose proportionality and effects of food.
The Prostate.
2022 02; 82(2):276-285. doi:
10.1002/pros.24271. [PMID: 34807458] - Bi-Juan Wang, Shih-Han Huang, Cheng-Li Kao, Christo J F Muller, Ya-Pei Wang, Kai-Hsiung Chang, Hui-Chin Wen, Chien-Chih Yeh, Li-Jane Shih, Yung-Hsi Kao, Shu-Pin Huang, Chia-Yang Li, Chih-Pin Chuu. Aspalathus linearis suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor.
PloS one.
2022; 17(7):e0270803. doi:
10.1371/journal.pone.0270803. [PMID: 35776912] - Lucie-Marie Scailteux, Fabien Despas, Frédéric Balusson, Boris Campillo-Gimenez, Romain Mathieu, Sébastien Vincendeau, André Happe, Emmanuel Nowak, Sandrine Kerbrat, Emmanuel Oger. Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: A French population-based study on prostate cancer patients.
British journal of clinical pharmacology.
2022 01; 88(1):336-346. doi:
10.1111/bcp.14972. [PMID: 34224605] - Jianqing Lin, Jacob Elkon, Brittany Ricart, Erica Palmer, Christian Zevallos-Delgado, Satish Noonepalle, Brooke Burgess, Robert Siegel, Yan Ma, Alejandro Villagra. Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.
The oncologist.
2021 12; 26(12):e2136-e2142. doi:
10.1002/onco.13957. [PMID: 34427023] - Valerie Carpenter, Tareq Saleh, So Min Lee, Graeme Murray, Jason Reed, Andrew Souers, Anthony C Faber, Hisashi Harada, David A Gewirtz. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
Biochemical pharmacology.
2021 11; 193(?):114765. doi:
10.1016/j.bcp.2021.114765. [PMID: 34536356] - Xiaoyu Li, Ke Cheng, Xinghai Li, Yuwen Zhou, Jiyan Liu, Hao Zeng, Yuanwei Chen, Xiao Liu, Ying Zhang, Yongsheng Wang, Feng Bi, Li Zheng. Phase I clinical trial of HC-1119: A deuterated form of enzalutamide.
International journal of cancer.
2021 10; 149(7):1473-1482. doi:
10.1002/ijc.33706. [PMID: 34109624] - Hui-Ming Lin, Blossom Mak, Nicole Yeung, Kevin Huynh, Thomas G Meikle, Natalie A Mellett, Edmond M Kwan, Heidi Fettke, Ben Tran, Ian D Davis, Kate L Mahon, Alison Zhang, Martin R Stockler, Karen Briscoe, Gavin Marx, Megan Crumbaker, Phillip D Stricker, Pan Du, Jianjun Yu, Shidong Jia, Tahlia Scheinberg, Michael Fitzpatrick, Paul Bonnitcha, David R Sullivan, Anthony M Joshua, Arun A Azad, Lisa M Butler, Peter J Meikle, Lisa G Horvath. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.
EBioMedicine.
2021 Oct; 72(?):103625. doi:
10.1016/j.ebiom.2021.103625. [PMID: 34656931] - Lisa M Cordes, Keith T Schmidt, Cody J Peer, Cindy H Chau, Erica Redmond, Deneise Francis, Fatima Karzai, Ravi A Madan, William D Figg. Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate Cancer.
The oncologist.
2021 09; 26(9):729-e1493. doi:
10.1002/onco.13919. [PMID: 34333820] - Matti Annala, Sinja Taavitsainen, Daniel J Khalaf, Gillian Vandekerkhove, Kevin Beja, Joonatan Sipola, Evan W Warner, Cameron Herberts, Amanda Wong, Simon Fu, Daygen L Finch, Conrad D Oja, Joanna Vergidis, Muhammad Zulfiqar, Bernhard J Eigl, Christian K Kollmansberger, Matti Nykter, Martin E Gleave, Kim N Chi, Alexander W Wyatt. Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021 08; 27(16):4610-4623. doi:
10.1158/1078-0432.ccr-21-1625. [PMID: 34083234] - Elena S Martens-Uzunova, Gina D Kusuma, Stefania Crucitta, Hong Kiat Lim, Crystal Cooper, James E Riches, Arun Azad, Takahiro Ochiya, Glen M Boyle, Melissa C Southey, Marzia Del Re, Rebecca Lim, Grant A Ramm, Guido W Jenster, Carolina Soekmadji. Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer.
Journal of extracellular vesicles.
2021 08; 10(10):e12136. doi:
10.1002/jev2.12136. [PMID: 34434533] - Mauro Gacci, Michele Marchioni, Piergustavo DE Francesco, Clara Natoli, Fabio Calabrò, Tania Losanno, Cito Gianmartin, Sergio Serni, Laura Doni, Cosimo DE Nunzio, Michele DE Tursi, Maurizio Valeriani, Silvana Giacinti, Mario Álvarez-Maestro, Marcello Scarcia, Giuseppe M Ludovico, Gabriella Del Bene, Giuseppe Simone, Mariaconsiglia Ferriero, Gabriele Tuderti, Pierluigi Bove, Anastasia Laudisi, Giuseppe Carrieri, Luigi Cormio, Paolo Verze, Roberto LA Rocca, Mario Falsaperla, Viviana Frantellizzi, Francesco Greco, Marta DI Nicola, Luigi Schips, Luca Cindolo. Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study.
Minerva urology and nephrology.
2021 08; 73(4):489-497. doi:
10.23736/s2724-6051.20.03723-6. [PMID: 32748613] - D A Leach, A Mohr, E S Giotis, E Cil, A M Isac, L L Yates, W S Barclay, R M Zwacka, C L Bevan, G N Brooke. The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells.
Nature communications.
2021 07; 12(1):4068. doi:
10.1038/s41467-021-24342-y. [PMID: 34210968] - M Del Re, V Conteduca, S Crucitta, G Gurioli, C Casadei, G Restante, G Schepisi, C Lolli, F Cucchiara, R Danesi, U De Giorgi. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide.
Prostate cancer and prostatic diseases.
2021 06; 24(2):524-531. doi:
10.1038/s41391-020-00309-w. [PMID: 33500577] - Lijie Zhou, Cai Zhang, Xiong Yang, Lilong Liu, Junyi Hu, Yaxin Hou, Hong Tao, Haruhiko Sugimura, Zhaohui Chen, Liang Wang, Ke Chen. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.
Clinical and translational medicine.
2021 06; 11(6):e449. doi:
10.1002/ctm2.449. [PMID: 34185414] - Mehdi Baratchian, Jeffrey M McManus, Mike P Berk, Fumihiko Nakamura, Sanjay Mukhopadhyay, Weiling Xu, Serpil Erzurum, Judy Drazba, John Peterson, Eric A Klein, Benjamin Gaston, Nima Sharifi. Androgen regulation of pulmonary AR, TMPRSS2 and ACE2 with implications for sex-discordant COVID-19 outcomes.
Scientific reports.
2021 05; 11(1):11130. doi:
10.1038/s41598-021-90491-1. [PMID: 34045511] - T Szarvas, A Csizmarik, M Váradi, T Fazekas, A Hüttl, P Nyirády, B Hadaschik, V Grünwald, S Tschirdewahn, S F Shariat, S Sevcenco, A Maj-Hes, G Kramer. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
Urologic oncology.
2021 05; 39(5):296.e11-296.e19. doi:
10.1016/j.urolonc.2020.09.005. [PMID: 33046366] - Mathieu Roumiguié, Xavier Paoletti, Yann Neuzillet, Romain Mathieu, Sebastien Vincendeau, François Kleinclauss, Arnaud Mejean, Laurent Guy, Marc Olivier Timsit, Thierry Lebret. Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis.
Future oncology (London, England).
2021 May; 17(14):1811-1823. doi:
10.2217/fon-2020-1104. [PMID: 33543650] - Samuel R Denmeade, Hao Wang, Neeraj Agarwal, David C Smith, Michael T Schweizer, Mark N Stein, Vasileios Assikis, Przemyslaw W Twardowski, Thomas W Flaig, Russell Z Szmulewitz, Jeffrey M Holzbeierlein, Ralph J Hauke, Guru Sonpavde, Jorge A Garcia, Arif Hussain, Oliver Sartor, Shifeng Mao, Harry Cao, Wei Fu, Ting Wang, Rehab Abdallah, Su Jin Lim, Vanessa Bolejack, Channing J Paller, Michael A Carducci, Mark C Markowski, Mario A Eisenberger, Emmanuel S Antonarakis. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2021 04; 39(12):1371-1382. doi:
10.1200/jco.20.02759. [PMID: 33617303] - Hsiu-Chi Lee, Chien-Hui Ou, Yun-Chen Huang, Pei-Chi Hou, Chad J Creighton, Yi-Syuan Lin, Che-Yuan Hu, Shih-Chieh Lin. YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer.
Oncogene.
2021 04; 40(13):2407-2421. doi:
10.1038/s41388-021-01718-4. [PMID: 33664454] - Karin Welén, Anna K Överby, Clas Ahlm, Eva Freyhult, David Robinsson, Anna Jonsson Henningsson, Johan Stranne, Daniel Bremell, Martin Angelin, Elisabeth Lindquist, Robert Buckland, Camilla Thellenberg Carlsson, Karlis Pauksens, Anna Bill-Axelsson, Olof Akre, Cecilia Ryden, Magnus Wagenius, Anders Bjartell, Anna C Nilsson, Johan Styrke, Johanna Repo, Åse Östholm Balkhed, Katarina Niward, Magnus Gisslén, Andreas Josefsson. COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Trials.
2021 Mar; 22(1):209. doi:
10.1186/s13063-021-05137-4. [PMID: 33726804] - Ali Ghoochani, En-Chi Hsu, Merve Aslan, Meghan A Rice, Holly M Nguyen, James D Brooks, Eva Corey, Ramasamy Paulmurugan, Tanya Stoyanova. Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer.
Cancer research.
2021 03; 81(6):1583-1594. doi:
10.1158/0008-5472.can-20-3477. [PMID: 33483372] - Fei Li, Ming Han, Pengfei Dai, Wei Xu, Juan He, Xiaoting Tao, Yang Wu, Xinyuan Tong, Xinyi Xia, Wangxin Guo, Yunjiao Zhou, Yunguang Li, Yiqin Zhu, Xiaoyu Zhang, Zhuang Liu, Rebiguli Aji, Xia Cai, Yutang Li, Di Qu, Yu Chen, Shibo Jiang, Qiao Wang, Hongbin Ji, Youhua Xie, Yihua Sun, Lu Lu, Dong Gao. Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide.
Nature communications.
2021 02; 12(1):866. doi:
10.1038/s41467-021-21171-x. [PMID: 33558541] - Abhinav Khanna, Luke P O'Connor, Prithvi B Murthy, Darren J Bryk, Michele Fascelli, Kyle Ericson, Nitin K Yerram, Samuel C Haywood, Robert Abouassaly. Contemporary management of advanced prostate cancer: an evolving landscape.
Clinical advances in hematology & oncology : H&O.
2021 Feb; 19(2):108-118. doi:
NULL. [PMID: 33596192] - Tibor Szarvas, Anita Csizmarik, Tamás Fazekas, András Hüttl, Péter Nyirády, Boris Hadaschik, Viktor Grünwald, Lukas Püllen, Zsolt Jurányi, Zsuzsa Kocsis, Shahrokh F Shariat, Sabina Sevcenco, Agnieszka Maj-Hes, Gero Kramer. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
BJU international.
2021 01; 127(1):44-55. doi:
10.1111/bju.15086. [PMID: 32314509] - Ali Abbasi, Ahmad Movahedpour, Ahmad Amiri, Mohamad Samare Najaf, Zohreh Mostafavi-Pour. Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer.
Current molecular medicine.
2021; 21(4):332-346. doi:
10.2174/1566524020666200903120344. [PMID: 32881669] - Prathesha Pillai, Ginil Kumar Pooleri, Shantikumar V Nair. Role of Testosterone Levels on the Combinatorial Effect of Boswellia serrata Extract and Enzalutamide on Androgen Dependent LNCaP Cells and in Patient Derived Cells.
Integrative cancer therapies.
2021 Jan; 20(?):1534735421996824. doi:
10.1177/1534735421996824. [PMID: 33615860] - Akiyo Hori, Haruka Sahashi, Sora Sano, Emiri Matsumiya, Maho Ariga, Akari Asano, Midori Soda, Chitoshi Goto, Takashi Mizui, Hisao Komeda, Kiyoyuki Kitaichi. Efficacy and Safety of Enzalutamide in a Real-World Cohort of Japanese Patients With Castration-resistant Prostate Cancer.
Anticancer research.
2020 Dec; 40(12):7101-7108. doi:
10.21873/anticanres.14739. [PMID: 33288609] - Cameron M Armstrong, Chengfei Liu, Liangren Liu, Joy C Yang, Wei Lou, Ruining Zhao, Shu Ning, Alan P Lombard, Jinge Zhao, Leandro S D'Abronzo, Christopher P Evans, Pui-Kai Li, Allen C Gao. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020 11; 26(22):6064-6074. doi:
10.1158/1078-0432.ccr-20-1682. [PMID: 32928794] - Yoko Koh, Atsunari Kawashima, Takeshi Ujike, Akira Nagahara, Kazutoshi Fujita, Hiroshi Kiuchi, Ryoichi Imamura, Yasushi Miyagawa, Norio Nonomura, Motohide Uemura. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
Anti-cancer drugs.
2020 11; 31(10):1099-1102. doi:
10.1097/cad.0000000000000986. [PMID: 32804697] - Mierxiati Abudurexiti, Wenkai Zhu, Yuchen Wang, Jun Wang, Wenhao Xu, Yongqiang Huang, Yao Zhu, Guohai Shi, Hailiang Zhang, Yiping Zhu, Yijun Shen, Bo Dai, Fangning Wan, Guowen Lin, Dingwei Ye. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
The Prostate.
2020 09; 80(12):950-961. doi:
10.1002/pros.24027. [PMID: 32648618] - Nima Sharifi. Homozygous HSD3B1(1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean?.
Annals of oncology : official journal of the European Society for Medical Oncology.
2020 09; 31(9):1103-1105. doi:
10.1016/j.annonc.2020.06.009. [PMID: 32592760] - Andrei Cristian Dan Gheorghe, Ana Ciobanu, Andreea Simona Hodorogea, George Daniel Radavoi, Viorel Jinga, Ioan Tiberiu Nanea, Gabriela Silvia Gheorghe. Evolution of Electrocardiographic Repolarization Parameters During Antiandrogen Therapy in Patients with Prostate Cancer and Hypogonadism.
Cardiovascular toxicology.
2020 08; 20(4):390-400. doi:
10.1007/s12012-020-09566-6. [PMID: 32152959] - Hongxi Wu, Linjun You, Yan Li, Zhili Zhao, Guangjiang Shi, Zhen Chen, Zhuo Wang, Xianjing Li, Shijia Du, Wanli Ye, Xiaofang Gao, Jingjing Duan, Yan Cheng, Weiyan Tao, Jinsong Bian, Jin-Rong Zhou, Qingyi Zhu, Yong Yang. Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance.
Cancer research.
2020 07; 80(13):2927-2939. doi:
10.1158/0008-5472.can-19-2549. [PMID: 32341037] - Guillemette E Benoist, Inge M van Oort, Emmy Boerrigter, Gerald W Verhaegh, Onno van Hooij, Levi Groen, Frank Smit, Pieter de Mol, Paul Hamberg, Vincent O Dezentjé, Niven Mehra, Winald Gerritsen, Diederik M Somford, Nielka P H van Erp, Jack A Schalken. Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study.
Clinical chemistry.
2020 06; 66(6):842-851. doi:
10.1093/clinchem/hvaa095. [PMID: 32408351] - M P Kolinsky, P Rescigno, D Bianchini, Z Zafeiriou, N Mehra, J Mateo, V Michalarea, R Riisnaes, M Crespo, I Figueiredo, S Miranda, D Nava Rodrigues, P Flohr, N Tunariu, U Banerji, R Ruddle, A Sharp, J Welti, M Lambros, S Carreira, F I Raynaud, K E Swales, S Plymate, J Luo, H Tovey, N Porta, R Slade, L Leonard, E Hall, J S de Bono. A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology.
2020 05; 31(5):619-625. doi:
10.1016/j.annonc.2020.01.074. [PMID: 32205016] - Marie-Liesse Joulia, Edith Carton, Anne Jouinot, Marie Allard, Olivier Huillard, Nihel Khoudour, Michaël Peyromaure, Marc Zerbib, Audrey Thomas Schoemann, Michel Vidal, François Goldwasser, Jérôme Alexandre, Benoit Blanchet. Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients.
Clinical genitourinary cancer.
2020 04; 18(2):155-160. doi:
10.1016/j.clgc.2019.05.020. [PMID: 31630979] - Guillemette E Benoist, Inge M van Oort, David M Burger, Niven Mehra, Nielka P van Erp. The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients.
Cancer chemotherapy and pharmacology.
2020 04; 85(4):753-760. doi:
10.1007/s00280-020-04039-7. [PMID: 32076807] - Keith T Schmidt, Cody J Peer, Alwin D R Huitema, Monique D Williams, Susan Wroblewski, Jan H M Schellens, Ravi A Madan, William D Figg. Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma.
Journal of pharmaceutical and biomedical analysis.
2020 Mar; 181(?):113073. doi:
10.1016/j.jpba.2019.113073. [PMID: 31927166] - Florian Rosar, Sebastian Dewes, Martin Ries, Andrea Schaefer, Fadi Khreish, Stephan Maus, Hendrik Bohnenberger, Johannes Linxweiler, Mark Bartholomä, Carsten Ohlmann, Samer Ezziddin. New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide.
European journal of nuclear medicine and molecular imaging.
2020 03; 47(3):687-694. doi:
10.1007/s00259-019-04674-0. [PMID: 31901103] - Eleni Efstathiou, Mark Titus, Sijin Wen, Patricia Troncoso, Anh Hoang, Paul Corn, Ina Prokhorova, John Araujo, Carl Dmuchowski, Amal Melhem-Bertrandt, Shiva Patil, Christopher J Logothetis. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
European urology oncology.
2020 02; 3(1):119-127. doi:
10.1016/j.euo.2019.01.008. [PMID: 31412017] - Lewis Thomas, Mehdi Baratchian, Nima Sharifi. Supraphysiologic Testosterone Solutions for Enzalutamide-resistant Prostate Cancer.
European urology.
2020 02; 77(2):156-157. doi:
10.1016/j.eururo.2019.07.037. [PMID: 31377027] - Changhua Ji, Mausumee Guha, Xu Zhu, Jessica Whritenour, Michelle Hemkens, Susanna Tse, Gregory S Walker, Ellen Evans, Nasir K Khan, Martin B Finkelstein, Ernesto Callegari, R Scott Obach. Enzalutamide and Apalutamide: In Vitro Chemical Reactivity Studies and Activity in a Mouse Drug Allergy Model.
Chemical research in toxicology.
2020 01; 33(1):211-222. doi:
10.1021/acs.chemrestox.9b00247. [PMID: 31538772] - Haley C Dahl, Mohammed Kanchwala, Shayna E Thomas-Jardin, Amrit Sandhu, Preethi Kanumuri, Afshan F Nawas, Chao Xing, Chenchu Lin, Daniel E Frigo, Nikki A Delk. Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence.
PloS one.
2020; 15(12):e0242970. doi:
10.1371/journal.pone.0242970. [PMID: 33326447] - Daniel P Petrylak, Nicholas J Vogelzang, Kamal Chatta, Mark T Fleming, David C Smith, Leonard J Appleman, Arif Hussain, Manuel Modiano, Parminder Singh, Scott T Tagawa, Ira Gore, Edward F McClay, Anthony E Mega, A Oliver Sartor, Bradley Somer, Raymond Wadlow, Neal D Shore, William C Olson, Nancy Stambler, Vincent A DiPippo, Robert J Israel. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
The Prostate.
2020 01; 80(1):99-108. doi:
10.1002/pros.23922. [PMID: 31742767] - Merel van Nuland, Andries M Bergman, Hilde Rosing, Niels de Vries, Alwin D R Huitema, Jos H Beijnen. Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer.
Pharmacotherapy.
2019 12; 39(12):1137-1145. doi:
10.1002/phar.2339. [PMID: 31596947] - Ashok Zakkula, Vinay Kiran, Umesh Todmal, Suresh P Sulochana, Ramesh Mullangi. RP-HPLC-UV Method for Simultaneous Quantification of Second Generation Non-Steroidal Antiandrogens Along with their Active Metabolites in Mice Plasma: Application to a Pharmacokinetic Study.
Drug research.
2019 Oct; 69(10):537-544. doi:
10.1055/a-0790-8309. [PMID: 30536259] - Kosuke Takemura, Masaya Ito, Yasukazu Nakanishi, Madoka Kataoka, Kazumasa Sakamoto, Hiroaki Suzuki, Ken-Ichi Tobisu, Fumitaka Koga. Serum γ-Glutamyltransferase as a Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide.
Anticancer research.
2019 Oct; 39(10):5773-5780. doi:
10.21873/anticanres.13780. [PMID: 31570481] - Molishree Joshi, Gergana E Stoykova, Maren Salzmann-Sullivan, Monika Dzieciatkowska, Lauren N Liebman, Gagan Deep, Isabel R Schlaepfer. CPT1A Supports Castration-Resistant Prostate Cancer in Androgen-Deprived Conditions.
Cells.
2019 09; 8(10):. doi:
10.3390/cells8101115. [PMID: 31547059] - Klara Kvorning Ternov, Jens Sønksen, Mikkel Fode, Henriette Lindberg, Caroline Michaela Kistorp, Rasmus Bisbjerg, Ganesh Palapattu, Peter Busch Østergren. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
BMJ open.
2019 09; 9(9):e030218. doi:
10.1136/bmjopen-2019-030218. [PMID: 31511288] - Cristian Lolli, Delia De Lisi, Vincenza Conteduca, Giorgia Gurioli, Emanuela Scarpi, Giuseppe Schepisi, Giorgia Ravaglia, Cecilia Menna, Alberto Farolfi, Amelia Altavilla, Salvatore Luca Burgio, Giuseppe Tonini, Daniele Santini, Ugo De Giorgi. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
The Prostate.
2019 08; 79(11):1211-1220. doi:
10.1002/pros.23804. [PMID: 31251826] - John Greene, Anne-Marie Baird, Orla Casey, Lauren Brady, Gordon Blackshields, Marvin Lim, Odharnaith O'Brien, Steven G Gray, Raymond McDermott, Stephen P Finn. Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide.
Scientific reports.
2019 07; 9(1):10739. doi:
10.1038/s41598-019-47189-2. [PMID: 31341219] - Noriya Yamaguchi, Shuichi Morizane, Tetsuya Yumioka, Hideto Iwamoto, Katsuya Hikita, Takehiro Sejima, Masashi Honda, Atsushi Takenaka. Flutamide as an Alternative Anti-androgen Agent and Predictor of the Efficacy of Novel Androgen Receptor-targeted Agents.
Anticancer research.
2019 Jul; 39(7):3879-3885. doi:
10.21873/anticanres.13538. [PMID: 31262916] - Kohei Hashimoto, Hidetoshi Tabata, Tetsuya Shindo, Toshiaki Tanaka, Jiro Hashimoto, Ryuta Inoue, Takashi Muranaka, Hiroshi Hotta, Masahiro Yanase, Yasuharu Kunishima, Atsushi Takahashi, Naoya Masumori. Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer.
Urologic oncology.
2019 07; 37(7):485-491. doi:
10.1016/j.urolonc.2019.04.026. [PMID: 31103335] - Merel van Nuland, Nikkie Venekamp, Willemijn M E Wouters, Huub H van Rossum, Hilde Rosing, Jos H Beijnen. LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide.
Journal of pharmaceutical and biomedical analysis.
2019 Jun; 170(?):161-168. doi:
10.1016/j.jpba.2019.03.043. [PMID: 30925273] - Sumanta K Pal, Dayson Moreira, Haejung Won, Seok Woon White, Pryanka Duttagupta, Marc Lucia, Jeremy Jones, JoAnn Hsu, Marcin Kortylewski. Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy.
International journal of molecular sciences.
2019 Apr; 20(8):. doi:
10.3390/ijms20081831. [PMID: 31013891] - Shiv Ram Krishn, Amrita Singh, Nicholas Bowler, Alexander N Duffy, Andrea Friedman, Carmine Fedele, Senem Kurtoglu, Sushil K Tripathi, Kerith Wang, Adam Hawkins, Aejaz Sayeed, Chirayu P Goswami, Madhukar L Thakur, Renato V Iozzo, Stephen C Peiper, William K Kelly, Lucia R Languino. Prostate cancer sheds the αvβ3 integrin in vivo through exosomes.
Matrix biology : journal of the International Society for Matrix Biology.
2019 04; 77(?):41-57. doi:
10.1016/j.matbio.2018.08.004. [PMID: 30098419] - Merel van Nuland, Steffie Groenland, Andre M Bergman, Joris I Rotmans, Hilde Rosing, Jos H Beijnen, Alwin D R Huitema. Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis.
Clinical genitourinary cancer.
2019 04; 17(2):e383-e386. doi:
10.1016/j.clgc.2018.12.004. [PMID: 30626533] - Takayuki Sumiyoshi, Kei Mizuno, Toshinari Yamasaki, Yu Miyazaki, Yuki Makino, Kosuke Okasho, Xin Li, Noriaki Utsunomiya, Takayuki Goto, Takashi Kobayashi, Naoki Terada, Takahiro Inoue, Tomomi Kamba, Akihiro Fujimoto, Osamu Ogawa, Shusuke Akamatsu. Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.
Scientific reports.
2019 03; 9(1):4030. doi:
10.1038/s41598-019-40719-y. [PMID: 30858508] - Vincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, Daniel Wetterskog, Samanta Salvi, Giorgia Gurioli, Emanuela Scarpi, Elena Castro, Mercedes Marin-Aguilera, Cristian Lolli, Giuseppe Schepisi, Antonio Maugeri, Anna Wingate, Alberto Farolfi, Valentina Casadio, Ana Medina, Javier Puente, Mª José Méndez Vidal, Rafael Morales-Barrera, Jose C Villa-Guzmán, Susana Hernando, Alejo Rodriguez-Vida, Aránzazu González-Del-Alba, Begoña Mellado, Enrique Gonzalez-Billalabeitia, David Olmos, Gerhardt Attard, Ugo De Giorgi. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
European urology.
2019 03; 75(3):368-373. doi:
10.1016/j.eururo.2018.09.049. [PMID: 30773204] - Masaki Shiota, Eiji Kashiwagi, Tomohiko Murakami, Ario Takeuchi, Kenjiro Imada, Junichi Inokuchi, Katsunori Tatsugami, Masatoshi Eto. Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.
Urologic oncology.
2019 03; 37(3):180.e19-180.e24. doi:
10.1016/j.urolonc.2018.10.020. [PMID: 30446464] - M van Nuland, N Venekamp, N de Vries, K A M de Jong, H Rosing, J H Beijnen. Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Feb; 1106-1107(?):26-34. doi:
10.1016/j.jchromb.2019.01.001. [PMID: 30639947] - Yan-Mei Liu, Peggy Wu, Risa Fukushi, Shunsuke Yamada, Qian Chen. Pharmacokinetics and Safety of Enzalutamide in Healthy Chinese Male Volunteers.
Clinical therapeutics.
2019 02; 41(2):261-268. doi:
10.1016/j.clinthera.2018.12.002. [PMID: 30642613] - Venecia Wilson, Xiaochun Lou, Donald J Osterling, Deanne F Stolarik, Gary Jenkins, Wenqing Gao, Geoff G Z Zhang, Lynne S Taylor. Relationship between amorphous solid dispersion in vivo absorption and in vitro dissolution: phase behavior during dissolution, speciation, and membrane mass transport.
Journal of controlled release : official journal of the Controlled Release Society.
2018 12; 292(?):172-182. doi:
10.1016/j.jconrel.2018.11.003. [PMID: 30408553] - Daksh Thaper, Sepideh Vahid, Ramandeep Kaur, Sahil Kumar, Shaghayegh Nouruzi, Jennifer L Bishop, Martin Johansson, Amina Zoubeidi. Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer.
Scientific reports.
2018 11; 8(1):17307. doi:
10.1038/s41598-018-35612-z. [PMID: 30470788] - Jelena Belic, Ricarda Graf, Thomas Bauernhofer, Yauheniya Cherkas, Peter Ulz, Julie Waldispuehl-Geigl, Samantha Perakis, Michael Gormley, Jaymala Patel, Weimin Li, Jochen B Geigl, Denis Smirnov, Ellen Heitzer, Mitchell Gross, Michael R Speicher. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
International journal of cancer.
2018 09; 143(5):1236-1248. doi:
10.1002/ijc.31397. [PMID: 29574703] - Se Young Choi, Jeman Ryu, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim. Prognostic factors of oncologic outcomes in metastatic chemotherapy-naïve castration-resistant prostate cancer treated with enzalutamide in actual clinical practice in East Asia.
Urologic oncology.
2018 09; 36(9):401.e11-401.e18. doi:
10.1016/j.urolonc.2018.06.004. [PMID: 30274641] - Patrick D Olson, Lisa K McLellan, Teri N Hreha, Alice Liu, Kelleigh E Briden, Keith A Hruska, David A Hunstad. Androgen exposure potentiates formation of intratubular communities and renal abscesses by Escherichia coli.
Kidney international.
2018 09; 94(3):502-513. doi:
10.1016/j.kint.2018.04.023. [PMID: 30041870] - Daniel Hettel, Ao Zhang, Mohammad Alyamani, Michael Berk, Nima Sharifi. AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
Endocrinology.
2018 08; 159(8):2884-2890. doi:
10.1210/en.2018-00283. [PMID: 29850791] - Remi Adelaiye-Ogala, Nur P Damayanti, Ashley R Orillion, Sreevani Arisa, Sreenivasulu Chintala, Mark A Titus, Chinghai Kao, Roberto Pili. Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma.
Cancer research.
2018 06; 78(11):2886-2896. doi:
10.1158/0008-5472.can-17-3386. [PMID: 29572225] - Guillemette E Benoist, Eric van der Meulen, Inge M van Oort, Jan H Beumer, Diederik M Somford, Jack A Schalken, David M Burger, Nielka P van Erp. Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer.
Therapeutic drug monitoring.
2018 04; 40(2):222-229. doi:
10.1097/ftd.0000000000000484. [PMID: 29419723] - Anuradha Jayaram, Daniel Wetterskog, Gerhardt Attard. Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test.
Cancer discovery.
2018 04; 8(4):392-394. doi:
10.1158/2159-8290.cd-18-0124. [PMID: 29610288] - Matti Annala, Gillian Vandekerkhove, Daniel Khalaf, Sinja Taavitsainen, Kevin Beja, Evan W Warner, Katherine Sunderland, Christian Kollmannsberger, Bernhard J Eigl, Daygen Finch, Conrad D Oja, Joanna Vergidis, Muhammad Zulfiqar, Arun A Azad, Matti Nykter, Martin E Gleave, Alexander W Wyatt, Kim N Chi. Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Cancer discovery.
2018 04; 8(4):444-457. doi:
10.1158/2159-8290.cd-17-0937. [PMID: 29367197] - Erica S Tsang, Marie de Haan, Bernhard J Eigl. A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2018 Mar; 24(2):143-145. doi:
10.1177/1078155216689381. [PMID: 28147927] - Benjamin A Teply, Hao Wang, Brandon Luber, Rana Sullivan, Irina Rifkind, Ashley Bruns, Avery Spitz, Morgan DeCarli, Victoria Sinibaldi, Caroline F Pratz, Changxue Lu, John L Silberstein, Jun Luo, Michael T Schweizer, Charles G Drake, Michael A Carducci, Channing J Paller, Emmanuel S Antonarakis, Mario A Eisenberger, Samuel R Denmeade. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
The Lancet. Oncology.
2018 01; 19(1):76-86. doi:
10.1016/s1470-2045(17)30906-3. [PMID: 29248236] - Michael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, Roman Gulati, Heather H Cheng, Jessica L Maes, Ruth F Dumpit, Peter S Nelson, Bruce Montgomery, Jeannine S McCune, Stephen R Plymate, Evan Y Yu. A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
PloS one.
2018; 13(6):e0198389. doi:
10.1371/journal.pone.0198389. [PMID: 29856824] - Hendrik Borgmann, Nada Lallous, Deniz Ozistanbullu, Eliana Beraldi, Naman Paul, Kush Dalal, Ladan Fazli, Axel Haferkamp, Pascale Lejeune, Artem Cherkasov, Martin E Gleave. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
European urology.
2018 01; 73(1):4-8. doi:
10.1016/j.eururo.2017.08.012. [PMID: 28851578] - Carolina Soekmadji, Anja Rockstroh, Grant A Ramm, Colleen C Nelson, Pamela J Russell. Extracellular Vesicles in the Adaptive Process of Prostate Cancer during Inhibition of Androgen Receptor Signaling by Enzalutamide.
Proteomics.
2017 Dec; 17(23-24):. doi:
10.1002/pmic.201600427. [PMID: 29105980] - Elizabeth A Wellberg, L Allyson Checkley, Erin D Giles, Stevi J Johnson, Robera Oljira, Reema Wahdan-Alaswad, Rebecca M Foright, Greg Dooley, Susan M Edgerton, Sonali Jindal, Ginger C Johnson, Jennifer K Richer, Peter Kabos, Ann D Thor, Pepper Schedin, Paul S MacLean, Steven M Anderson. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer.
Hormones & cancer.
2017 12; 8(5-6):269-285. doi:
10.1007/s12672-017-0302-9. [PMID: 28741260] - V Conteduca, E Scarpi, P Caroli, S Salvi, C Lolli, S L Burgio, C Menna, G Schepisi, S Testoni, G Gurioli, G Paganelli, V Casadio, F Matteucci, U De Giorgi. Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Scientific reports.
2017 Nov; 7(1):15541. doi:
10.1038/s41598-017-15928-y. [PMID: 29138500] - Khalid Z Masoodi, Kurtis Eisermann, Zhenyu Yang, Javid A Dar, Laura E Pascal, Minh Nguyen, Katherine O'Malley, Erica Parrinello, Firuz G Feturi, Alex N Kenefake, Joel B Nelson, Paul A Johnston, Peter Wipf, Zhou Wang. Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone.
Endocrinology.
2017 10; 158(10):3152-3161. doi:
10.1210/en.2017-00408. [PMID: 28977599] - Yoshiaki Ohtsu, Jacqueline A Gibbons, Katsuhiro Suzuki, Michael E Fitzsimmons, Kohei Nozawa, Hiroshi Arai. Absorption, Distribution, Metabolism, and Excretion of the Androgen Receptor Inhibitor Enzalutamide in Rats and Dogs.
European journal of drug metabolism and pharmacokinetics.
2017 Aug; 42(4):611-626. doi:
10.1007/s13318-016-0374-x. [PMID: 27590197] - Lee S Schwartzberg, Denise A Yardley, Anthony D Elias, Manish Patel, Patricia LoRusso, Howard A Burris, Ayca Gucalp, Amy C Peterson, Martha E Blaney, Joyce L Steinberg, Jacqueline A Gibbons, Tiffany A Traina. A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017 Aug; 23(15):4046-4054. doi:
10.1158/1078-0432.ccr-16-2339. [PMID: 28280092] - Alicja Puszkiel, Alain Plé, Olivier Huillard, Gaëlle Noé, Constance Thibault, Stéphane Oudard, François Goldwasser, Michel Vidal, Jérome Alexandre, Benoit Blanchet. A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2017 Jul; 1058(?):102-107. doi:
10.1016/j.jchromb.2017.04.014. [PMID: 28545929]